Anvisa aprova venda de Paxlovid em farmácias brasileiras

Pfizer gains expanded market access in Brazil's private healthcare sector while regulatory framework preserves public system supply chains. Reflects ongoing tension between pharmaceutical commercialization and universal healthcare commitments in developing economies.

Similar to post-pandemic pharmaceutical distribution patterns in middle-income countries where dual public-private systems create tiered access to treatments based on economic capacity.

Brazilian consumers with COVID-19 symptoms and elevated severity risk now have private access to Paxlovid via prescription, though pricing remains undisclosed. This expands treatment options beyond public SUS system but creates potential two-tiered access based on ability to pay.

Regulatory approval balances private market expansion with public health priorities through SUS supply prioritization. Government may face pressure to regulate pricing, ensure equitable access, and monitor supply chain. Potential for future price controls or reimbursement negotiations with Pfizer.